Designing modulators of PI 3-kinase delta (PI3Kdelta) for the treatment of haematological malignancies

这项提议旨在创造能够控制一种名为PI3K Delta的蛋白质的药物，用于治疗血癌，如急性淋巴细胞性白血病(ALL)。它是基于我们的团队提供的临床洞察力，他们正在治疗这种疾病的患者，并认识到需要改进治疗方法。我们发现了PI3K Delta，并在这个分子上拥有长期的专业知识。我们相信，我们已经找到了调整PI3K Delta治疗白血病的新方法，现在我们希望在阿斯利康的帮助下，将这些概念转化为药物。

This proposal is aimed at creating medicines that can control a protein called PI3Kdelta, for use in the treatment of blood cancers such as acute lymphoblastic leukaemia (ALL). It is based on clinical insight provided by our team, who are treating patients with this disease and recognise the need for improved therapies. We discovered PI3Kdelta and have long-term expertise on this molecule. We believe we have found news ways to modulate PI3Kdelta to treat leukaemia, and would now like to turn these concepts into a medicine, with the help of AstraZeneca.